Menu
Wechat public account

About CapitalBio

Location:Home - About CapitalBio - Events

Events

2025

1.The world's first personalized music/color-therapeutic medicinal cuisine restaurant, Qilingxuan, based on both physical and mental conditioning.

2.Establishment and Clinical Promotion of the Key Technical Platform for Laboratory Diagnosis of Multidrug-Resistant Bacteria Resistance and Pathogenicity won the Second Prize of the Beijing Science and Technology Progress Award.

3.Development and Clinical Application of the Microfluidics-based Genetic Testing System for Hereditary Deafness won the Second Prize of the Beijing Technological Invention Award.

4.Collaborated to establish the "Beijing Key Laboratory of Engineering Science for Intelligent Chinese Medicine," which was officially designated as a Beijing Key Laboratory in 2025.

5.The “TCM Sclera Shadowless Imaging Health Intelligent Analysis System” has won the first prize of Huang Jiasi Biomedical Engineering Award, which is the highest science and technology award in the field of biomedical engineering in China.

6.CapitalBio’s project on etiological mechanisms and prevention and control technologies for adverse pregnancy outcomes and birth defects obtained the Second Prize of National Science and Technology Progress Award.

2024

1.The Molecular Materia Medica technology won the Huaxia Medical Science and Technology Award.

2.The Molecular Materia Medica technology won the first prize of International Award for Contribution to Chinese Medicine-Achievement Award in Medical Science.

3.The Molecular Materia Medica technology was selected for inclusion in Traditional Chinese Medicine Regulatory Science.

4.The research project on Key Technologies for Rapid Detection of Major Infectious Disease Pathogens at Ports of Entry was evaluated as the First-Class Seitech Achievement of China Customs by the General Administration of Customs of the People's Republic of China.

5.CapitalBio Pharma won the title of "Specialized, Refined, Distinctive, and Innovative" Enterprise in Beijing.

6.CapitalBio AiDevice Corporation was established, aiming to the modernization of traditional Chinese medicine diagnostic sector.

2023

1.Won the title of “Specialized, Refined, Distinctive, and Innovative" Enterprise in Beijing.”

2.The technology of Molecular Compendium of Materia Medica won the highest award in the final of the National Disruptive Technology Innovation Competition hosted by the Ministry of Science and Technology - the Excellence Award.

3.The “development and application program of fully-integrated chip laboratory system” won the first prize of Huang Jiasi Biomedical Engineering Award, which is the highest science and technology award in the field of biomedical engineering in China.

4.CapitalBio Pharma was awarded the title of "National High tech Enterprise" jointly recognized by the Ministry of Science and Technology, the Ministry of Finance, and the State Administration of Taxation.

5.The first fully automated and intelligent high-throughput screening laboratory for traditional Chinese medicine in the world was constructed.

6.CapitalBio's establishment and application of traditional chinese medicine constitution identification system obtained the Second Prize of National Science and Technology Progress Award.

2022

1.The "Traditional Chinese Medicine Multidisciplinary Innovation Team for Heart Failure Treatment" led by CapitalBio Corporation was selected as a multidisciplinary innovation team by the National Administration of Traditional Chinese Medicine, ranking first among all participating teams.

2.Two more national standards for precision medical testing technology have been added, and 24 national and industry standards have been drafted and promulgated for implementation.

3.CapitalBio's SARS-CoV-2 Nucleic Acid Detection Kit (Fluorescent PCR Method) has obtained the medical device registration certificate approved by NMPA and CE-IVD certification.

2021

1.CapitalBio Pharma Corporation was established, aiming to the modernization of traditional Chinese medicine.

2.SARS-CoV-2NucleicAcid Detection System (Integrated Isothermal Amplification Chip Method) was approved by NMPA as an emergency medical device and obtained CE-IVD certificate.

3.CapitalBio's Twenty-three Deafness-RelatedGene Mutations Detection Kit (Microfluidic Chip Method) was approved by NMPA.

4.Fully-automated Mid-throughput Pre-analytical System and Full-automatic High-throughput Nucleic Acid Extraction and Purification Instrument obtained Medical Device Registration Certificate.

5.The achievement video of “Fully Integrated Chip Laboratory System for SARS-CoV-2 Nucleic Acid Detection” won the first “2021 CAETS Communications Prize for Engineering Success Stories”.

6.“Portable Fully-integratedChip System for On-site Rapid Detection of Forensic DNA Evidence” of CapitalBio Technology won the “First Prize of Science and Technology Award of Ministry of Public Security”.

2020

1.On March 2, 2020, Chinese President Xi Jinping listened to the report by Prof. Cheng Jing, Member of Chinese Academy of Engineering, on CapitalBio’s “Microfluidic detection kit for the six respiratory viruses” (SARS-CoV-2 is among these six viruses) approved by the National Medical Products Administration (NMPA).

2.On February 28, 2020, then Chinese Premier Li Keqiang listened to the report by Prof. Cheng Jing, Member of Chinese Academy of Engineering, on CapitalBio’s “Microfluidic detection kit for the six respiratory viruses” and also the equipment approved by the NMPA.

3.The "Respiratory Virus Nucleic Acid Detection Kit (Isothermal Amplification on Disk Chip)" (SARS-CoV-2 is among these viruses) was issued with NMPA and CE-IVD certificate.

4.To battle against the COVID-19 outbreak in Wuhan, CapitalBio donated 12,000 sets of “Microfluidic detection kit for the six respiratory viruses” , which is worth more than 5 million Yuan, to the Union Hospital of HUST, Tongji Hospital of HUST, Huoshenshan Hospital and Hubei Provincial People's Hospital.

2019

1.CapitalBio’s Genotype and Drug Resistance Detection Kit for Hepatitis B Virus (microarray) was approved by CFDA.

2.CapitalBio Technology’s ‘LeiJingTang’ Health Management Center was opened in Beijing.

3.Rewriting Life Stories with Genetic Technology: Newborn Screening for Hereditary Deafness Genes Exceeds 4 Million.The total volume of non-invasive prenatal genetic screening has exceeded 2 million.

4.CapitalBio’s RTsochipTM-W High-throughput Isothermal Nucleic Acid Amplification Microfluidic Chip Analyzer was approved by CFDA.

5.CapitalBio’s Automatic Biochemistry Analyzer and Glucose & Lipid Panel 3 Detection Kit were approved by CFDA.

6.On August 11, 2019, CHIPSCREEN BIOSCIENCES(688321.SS), an innovative drug research and development company launched by CapitalBio Corporation, successfully went public on Shanghai Stock Exchange.

2018

1.CapitalBio Technology built the health - related products manufacturing facilities in Chongqing.

2.Twenty two national standards and IVD industrial standards drafted by CapitalBio have been promulgated.

3.The number of people screened by CapitalBio Technology’s community diabetes screening program exceeded 100,000, in the Liangjiang District, Chongqing. Among them, nearly 10,000 were identified as newly discovered patients with diabetes, more than those that have already been diagnosed.

4.CapitalBio Technology’s ‘LeiJingTang’ Health Management Center was opened in Pudong, Shanghai.

5.CapitalBio Technology was restructured by auguring CapitalBio MedLab, CapitalBio eHealth, CapitalBio Dx, and CapitalBio Genomics.

6.CapitalBio’s Sclera Imaging System was approved by CFDA.

7.CapitalBio’s gene chip for hereditary deafness detection obtained the Second Prize of National Technology Invention Award.

8.CapitalBio Technology’s companion diagnostic gene chip for anti-thrombus treatment (microarray) was approved by CFDA.

2017

1.CapitalBio Technology launched the microRNA +AFP combined testing for early detection of liver cancer.

2.The pilot clinical validation of the common hereditary deafness gene detection kit for Caucasian population was accomplished in USA.

3.New CapitalBio Technology facilities for scientific and medical testing services were built in Shanghai.

4.CapitalBio Technology’s health management program for the prevention and treatment of diabetes in local community was initiated in the Liangjiang District, Chongqing.

5.CapitalBio Technology’s ‘LeiJingTang’ Health Management Center combining modern science and technology and traditional medicine officially started to provide diversified services.

6.Tuberculosis and Non-Tuberculous Mycobacteria Real-Time PCR Detection Kit, Mycobacterial Species Identification Array Kit, Nine Deafness Gene Mutations Detection Kit, Thalassemia Gene Mutations Detection Kit, and LuxScanTM 10K Microarray Scanner obtained medical device registration certificates issued by Food and Drug Administration of National Public Health Ministry of Thailand.

7.Shanghai Branch Center of NERCBBT was established.

8.Seven more CapitalBio Medlab’s subsidiaries were approved to be the National Demonstration Center for the Application of Gene Detection Technology by NDRC.

2016

1.Won the title of “National Intellectual Property Model Enterprise”.

2.Hereditary Deafness Gene Detection Kit (microarray) and LuxScanTM 10K Microarray Scanner was approved for use in local hospitals by the Department of Social Benefit in Taiwan.

3.CapitalBio MedLab set up 23 subsidiaries nationwide, 16 of which were approved to be the National Demonstration Center for the Application of Gene Detection Technology by NDRC.

4.CapitalBio Technology’s Respiratory Pathogens Nucleic Acid Detection Kit microfluidics, Thalassemia Gene Mutations Detection Kit (microarray), EasyArrayTM 3A Automatic Biochip Reaction Reader, Estradiol, Testosterone, Progesterone, and β2-Microglobulin reagents for Immunoassay (magnetic particle chemiluminescence immunoassay) were approved by CFDA certificates; The Flow Cytometry was issued with CFDA and CE certificates; the fully automated immuno-chemiluminescence analyzer ChemLiteTM 1200 obtained CE certificate.

5.CapitalBio Technology’s full-integrated DNA profile analyzer/target gene sequencer Quick TargSeqTM and water-proof RTisochipTM isothermal nucleic acid amplification microfluidic chip analyzer were launched.

6.CapitalBio Technology’s Sclera Imaging System won China’s Red Star Design Award.

7.CapitalBio Technology launched the Gut Microbiota Analysis, Genetic Test of Diabetes, Natural Herbal Drinks for Body Constitution Adjustment, Probiotic Powder.

8.CapitalBio Technology’s industrial base for NGS system manufacturing and medical testing in Guandong was built.

9.The Livestock and Poultry Breeding Branch Center of NERCBBT was established in Beijing.

2015

1.CapitalBio MedLab became the pilot unit of the first batch approved by the National Health Commission to use high-throughput sequencing for tumor diagnosis and treatment.

2.CapitalBio Technology’s manufacturing facilities for clinical diagnostic products and service facilities for medical testing service were completed in Chengdu.

3.CapitalBio Technology’s Gene Chip for Diseases Susceptibility Testing, Ultra-early Detection for Tumor, Microfluidic Chip-based Fully Integrated Blood Chemistry Testing System, Sclera Imaging System, Portable Dynamic Air Quality Monitor, Multi-Functional Chair for Seniors, Natural Herbal Drinks for Body Constitution Adjustment, Special Tea for Lowing the Blood Sugar and Triglyceride and other “measuring – adjustment –enhancing” health related products.

4.CapitalBio Technology’s HPV Genotyping Detection Kit (microarray) was approved by CFDA.

5.Yantai branch-center of NERCBBT was officially established.

6.CapitalBio Technology’s BioelectronSeqTM 4000 Sequencer, Fetal Chromosome Aneuploidy (T21, T18, T13) Testing Kit (Semiconductor Sequencing) and RTisochipTM Isothermal Nucleic Acid Amplification Microfluidic Chip Analyzer was approved by CFDA.

2014

1.CapitalBio’s Fifteen Deafness-related Gene Mutations Detection Kit (microarray) was approved by CFDA.

2.CapitalBio’s next generation high-throughput sequencer was launched.

3.CapitalBio MedLab became the pilot unit of the first batch approved by National Health Commission to use next generation sequencing for the diagnosis of genetic diseases, the prenatal screening & diagnosis, and the preimplantation genetic diagnosis.

4.CapitalBio Genomics,CapitalBio Dx and CapitalBio eHealth were established, aiming to provide a comprehensive solution to health management.

2013

1.CapitalBio’s integrated DNA chip work station EasyArrayTM 3A and isothermal nucleic acid amplification microfluidic chip analyzer RTisochipTM were launched.

2.CapitalBio MedLab was approved by the National Health Commission to be the first pilot unit for independent medical testing for personalized medicine, authorized to validate, evaluate and provide the self-developed laboratory tests for personalized medicine requested by hospitals.

2012

1.CapitalBio’s fully automated chemiluminescence immunoassay analyzer ChemLite 1200TM and the fully automated liquid handling station LabKeeperTM were launched.

2.Three national standards for biochips drafted by CapitalBio Corporation were issued by General Administration of Quality Supervision, Inspection and Quarantine.

3.CapitalBio Technology and CapitalBio MedLab were established; CapitalBio Corporation entered the era of operating as a group company.

4. The world largest Genetic Screening Program of Inherited Hearing Loss for Newborns was initiated in Beijing in 2012.

5. Branch-centers in Ningbo, Ningxia, Shanxi and Xinjiang were granted with the name plate by NDRC.

2011

1.Genetic Screening Program of Inherited Hearing Loss for the deaf in Beijing was accomplished.

2010

1.CapitalBio’s M. tuberculosis Drug Resistance Detection Kit (microarray) was approved by CFDA.

2.Won the honorary title of “Pilot Unit of Intellectual Property of National Enterprises and Institutions”.

3.CapitalBio’s high-throughput microarray scanner LuxScanTM HT 24 was launched.

4.Signed strategic cooperation agreement with Roche. Signed strategic cooperation agreements on translational medicine with General Hospital of PLA and People’s Hospital of Peking University.

5.CapitalBio’s Mycobacterial Species Identification Kit (microarray) was approved by CFDA.

2009

1.CapitalBio’s laser confocal scanner LuxScanTM10K received the title of “China National Innovative Product”.

2.The Biobank of Chinese Hematopoietic Stem Cell Donors was established and physically located in CapitalBio.

3.CapitalBio’s Auto-antibody (eight items) Detection Kit (microarray) was approved by CFDA.

4.CapitalBio’s Nine Deafness Gene Mutations Detection Kit (microarray) was approved by CFDA.

5.The nest generation work station for high density gene chip was first launched in China by CapitalBio.

2008

1.The first IVD industrial standard for biochip drafted by CapitalBio was issued by CFDA.

2007

1.The biochip instruments developed by CapitalBio won the Second Prize of National Technological Invention Award.

2.The National Engineering Research Center for Beijing Biochip Technology (NERCBBT) passed the acceptance by National Development and Reform Commission NDRC. Its first branch center - Xinjiang Branch Center was established.

3.Laboratory accreditation certificate (CNASL2451) was issued by China National Accreditation Service for Conformity Assessment.

2006

1.CapitalBio’s service “HLA typing by gene chip ” was adopted by China Marrow Donor Program.

2.Published papers on microarray developed by CapitalBio itself in Nature Biotechnology. Recommended by Nature as global supplier of microarray chips and services.

2005

1.ISO9001 and ISO13485 certificates was issued.

2.CapitalBio’s laser confocal scanner LuxScanTM 10 KB was approved by CFDA.

3.Established strategic partnership with Affymetrix.

2004

1.CapitalBio’s first CCD-based microarray scanner EcoScanTM-100 was approved by CFDA.

2.China’s first laser confocal scanner LuxScanTM 10K exported to the United States of America.

2003

1.The new headquarter located in the Zhongguancun Life Science Park in Beijing was completed.

2.Launched China’s first CCD-based microarray scanner.

2002

1.CapitalBio’s first international patent for biochips was allowed.

2001

1.Prof. CHENG Jing edited the world first English monograph on biochips.

2.The National Engineering Research Center for Beijing Biochip Technology (NERCBBT) officially established.

3.Capitalbio’s electromagnetic biochip was rated as “One of China’s Top 10 Advances in Science & Technology in 2000” by the academicians of Chinese Academy of Sciences and Chinese Academy of Engineering.

2000

1.CapitalBio Corporation was incorporated.

Copyright © 2000-2023博奥生物集团有限公司 京ICP备14023013号-3

《互联网药品信息服务资格证书》: (京) - 非经营性-2016-0047 京公网安备11011402013114号